Ivermectin induced Steven-Johnsons syndrome: case report

Desmond Aroke, Diego Nitcheu Tchouakam, Alexis Tazinya Awungia, Sylvester Yari Mapoh, Stewart Ndutard Ngassa, Benjamin Momo Kadia, Desmond Aroke, Diego Nitcheu Tchouakam, Alexis Tazinya Awungia, Sylvester Yari Mapoh, Stewart Ndutard Ngassa, Benjamin Momo Kadia

Abstract

Background: Stevens-Johnson syndrome is one of the manifestations of mucocutaneous adverse drug reactions. Although antimicrobials are responsible for greater than 50% of these adverse drug reactions, there is no documented case implicating ivermectin as the culprit. A 38 year old adult Cameroonian male presented to our health facility with facial rash, painful oral sores, black eschars on lips and red tearing eyes 3 days following ingestion of ivermectin received during a nationwide anti-filarial campaign. He had no known chronic illness, no known allergies and was not on any medications prior to the campaign. Physical examination revealed discharging erythematous eyes, crusted and blister-like lesions with cracks on his lips and oral mucosa. His laboratory tests were unremarkable but for a positive Human Immunodeficiency Virus (HIV) test. A diagnosis of Ivermectin induced Stevens-Johnson syndrome in a newly diagnosed HIV patient was made. The patient was managed with supportive therapy and the evolution thereafter was favourable.

Conclusion: Stevens-Johnson syndrome is a potential side effect of ivermectin and susceptibility to this adverse effect may be increased in HIV infection.

Keywords: Human immunodeficiency virus (HIV); Ivermectin; Stevens–Johnson syndrome (SJS).

Figures

Fig. 1
Fig. 1
Photo of lesions on the lips
Fig. 2
Fig. 2
Photo of facial rash

References

    1. Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625–645.
    1. Tiwari P, Panik R, Bhattacharya A, Ahirwar D, Chandy A. Toxic epidermal necrolysis : an update. Asian Pac J Trop Dis. 2013;3(2):85–92. doi: 10.1016/S2222-1808(13)60051-1.
    1. Tyagi S, Kumar S, Kumar A, Singla M, Singh A. Stevens–Johnson syndrome—a life threatening skin disorder: a review. J Chem Pharm Res. 2010;2(2):618–626.
    1. Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgr Med. 2011;57(2):115–119. doi: 10.4103/0022-3859.81865.
    1. Bhounsule SA, Bandodkar LV, Samuel LJ. Retrospective analysis of deaths due to drug- induced Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in inpatients admitted in the dermatology unit of a tertiary care hospital. J Pharm Biol Sci. 2015;10(4):96–99.
    1. Ofoma UR, Chapnick EK. Fluconazole induced toxic epidermal necrolysis: a case report. Cases J. 2009;2:9071. doi: 10.1186/1757-1626-2-9071.
    1. Adinma E, Ezeama NN, Umeokonkwo CD. Streptomycin-induced Steven–Johnson syndrome in a HIV sero-positive patient with tuberculosis: a case report. Int J Clin Med. 2011;2:481–483. doi: 10.4236/ijcm.2011.24082.
    1. Rajput R, Sagari S, Durgavanshi AKA. Paracetamol induced Steven–Johnson syndrome. A rare case report. Contemp Clin Dent. 2015;6(Suppl 1):S278–S281. doi: 10.4103/0976-237X.166838.
    1. Coopman SA, Johnson RA. PR and SRS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670–1674. doi: 10.1056/NEJM199306103282304.
    1. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NAGN. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol. 2007;7:8. doi: 10.1186/1472-6904-7-8.
    1. Sharma VK, Sethuraman GKB. Cutaneous adverse drug reactions: clinical pattern and causative agents—a 6 year series from Chandigarh, India. J Postgr Med. 2001;47:95–99.
    1. Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: an overview. J Postgr Med. 1996;42:15–22.
    1. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol. 2008;74(4):430. doi: 10.4103/0378-6323.42883.
    1. Lehloenya R. Management of Stevens–Johnson syndrome and toxic epidermal necrolysis. Curr Allergy Clin Immunol. 2007;20(3):124–128.
    1. Kircik LH, Del Rosso JQ, Layton AMSJ. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15(3):325–332.
    1. Nirken MH. Stevens–Johnson syndrome and toxic epidermal necrolysis in adults. . Accessed 5 Jan 2017
    1. Paquet P, Pierard GEQP. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell’s syndrome) Int Arch Allergy Immunol. 2005;136:205–216. doi: 10.1159/000083947.
    1. Roujeau JC, Chosidow O, Saiag PGJ. Toxic epidermal necrolysis (Lyell syndrome) J Am Acad Dermatol. 1990;23:1039–1058. doi: 10.1016/0190-9622(90)70333-D.
    1. Praag EV. Ivermectin. In: Drugs for rabbits. 2009. p. 2–5.
    1. Richard F, Michelle A. Clark LXC. Lippincott’s illustrated reviews: pharmacology, 4th ed. In: Richard A, Harvey PCC, editors. Philadelphia: Lippincott Williams & Wilkins; 2009.
    1. Shinohara EH, Martini MZ, Gomes H, Neto DO. Oral myiasis treated with ivermectin: case report. Braz Dent J. 2004;15(1):79–81. doi: 10.1590/S0103-64402004000100015.
    1. Catherine D, Susana F, Elisabeth G, Martine M, Christian S. Encephalopathy due to prolonged misuse of ivermectin (Stromectol®) after scabies infection. Clin Toxicol. 2014;160(1):1.
    1. Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. CID. 2007;44(1):53–60. doi: 10.1086/509325.
    1. WHO African programme for onchocerciasis control: progress report, 2013–2014. Wkly Epidemiol Rec. 2014;374(49):545–560.
    1. WHO. Prevention, control and elimination of onchocerciasis; 2015. . Accessed 5 Jan 2017
    1. MSD BV. Stromectol (Ivermectin) tablets; 2009. p. 1–6. . Accessed 5 Jan 2017
    1. U.S. Food and Drug Administration Medwatch. What is a serious adverse event? . Accessed 5 Jan 2017

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner